MTDH mediates trastuzumab resistance in HER2 positive breast cancer by decreasing PTEN expression through an NFκB-dependent pathway | |
Cheng Du1; Xiaomin Yi2; Wenchao Liu2; Tao Han1; Zhaozhe Liu1; Zhenyu Ding1; Zhendong Zheng1; Ying Piao1; Jianlin Yuan2; Yaling Han1; Manjiang Xie2; Xiaodong Xie1 | |
2014-01-01 | |
Source Publication | BMC Cancer
![]() |
ISSN | 1471-2407 |
Volume | 14Issue:1 |
Abstract | Trastuzumab resistance is almost inevitable in the management of human epidermal growth factor receptor (HER) 2 positive breast cancer, in which phosphatase and tensin homolog deleted from chromosome 10 (PTEN) loss is implicated. Since metadherin (MTDH) promotes malignant phenotype of breast cancer, we sought to define whether MTDH promotes trastuzumab resistance by decreasing PTEN expression through an NFκB-dependent pathway. |
Language | 英语 |
Document Type | 期刊论文 |
Identifier | http://ir.imr.ac.cn/handle/321006/159390 |
Collection | 中国科学院金属研究所 |
Affiliation | 1.Institute of Metal Research, Chinese Academy of Sciences 2.中国人民解放军第四军医大学 3.Department of Urology |
Recommended Citation GB/T 7714 | Cheng Du,Xiaomin Yi,Wenchao Liu,et al. MTDH mediates trastuzumab resistance in HER2 positive breast cancer by decreasing PTEN expression through an NFκB-dependent pathway[J]. BMC Cancer,2014,14(1). |
APA | Cheng Du.,Xiaomin Yi.,Wenchao Liu.,Tao Han.,Zhaozhe Liu.,...&Xiaodong Xie.(2014).MTDH mediates trastuzumab resistance in HER2 positive breast cancer by decreasing PTEN expression through an NFκB-dependent pathway.BMC Cancer,14(1). |
MLA | Cheng Du,et al."MTDH mediates trastuzumab resistance in HER2 positive breast cancer by decreasing PTEN expression through an NFκB-dependent pathway".BMC Cancer 14.1(2014). |
Files in This Item: | There are no files associated with this item. |
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.
Edit Comment